应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BK4139 生物科技
已收盘 12-08 16:00:00 EST
1,117.49
-12.18
-1.08%
最高
1,135.36
最低
1,116.07
成交量
8.02亿
今开
1,129.68
昨收
1,129.68
日振幅
1.71%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
207.68亿
换手率
--
流通股本
0.00
市净率
7.241142
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Praxis Precision Medicines, Inc.:单药疗法研究Power3计划于2026年上半年启动
美股速递 · 05:47
Praxis Precision Medicines, Inc.:单药疗法研究Power3计划于2026年上半年启动
因塞特医疗在2025年ASH大会上发布更新的积极数据,巩固了其首个靶向Mutcalr单克隆抗体Inca033989在原发性血小板增多症患者中的潜力
美股速递 · 05:39
因塞特医疗在2025年ASH大会上发布更新的积极数据,巩固了其首个靶向Mutcalr单克隆抗体Inca033989在原发性血小板增多症患者中的潜力
Assembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果,显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低
美股速递 · 05:14
Assembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果,显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低
Cardiff Oncology公布在ASH 2025中与Onvansertib联合进行的慢性骨髓单核细胞白血病的临床试验数据
美股速递 · 05:06
Cardiff Oncology公布在ASH 2025中与Onvansertib联合进行的慢性骨髓单核细胞白血病的临床试验数据
Arcutis加强董事会 新任命Amit Munshi并致敬退休的Bhaskar Chaudhuri
美股速递 · 05:00
Arcutis加强董事会 新任命Amit Munshi并致敬退休的Bhaskar Chaudhuri
Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好
美股速递 · 12-08 23:43
Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好
Syndax公布AML联合疗法强劲数据
环球市场播报 · 12-08 23:42
Syndax公布AML联合疗法强劲数据
Recursion Pharmaceuticals股价上涨6.1%,因其实验性疗法在稀有疾病试验中减少了息肉生长
美股速递 · 12-08 22:34
Recursion Pharmaceuticals股价上涨6.1%,因其实验性疗法在稀有疾病试验中减少了息肉生长
ARCELLX, INC. 股份上涨10%,因公司公布其多发性骨髓瘤癌症疗法中期试验的积极数据
美股速递 · 12-08 22:34
ARCELLX, INC. 股份上涨10%,因公司公布其多发性骨髓瘤癌症疗法中期试验的积极数据
Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨,接近一年高点,最后上涨20.5%
美股速递 · 12-08 22:34
Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨,接近一年高点,最后上涨20.5%
Mirum Pharma首席执行官表示,Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元
美股速递 · 12-08 21:43
Mirum Pharma首席执行官表示,Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元
Coherus公布六年Jupiter-02随访结果显示Loqtorzi®联合化疗几乎使鼻咽癌的中位整体生存期增加一倍
美股速递 · 12-08 21:33
Coherus公布六年Jupiter-02随访结果显示Loqtorzi®联合化疗几乎使鼻咽癌的中位整体生存期增加一倍
Ernexa Therapeutics在美国血液学会年会上发布卵巢癌治疗领先细胞治疗候选药物的新临床前数据
美股速递 · 12-08 21:31
Ernexa Therapeutics在美国血液学会年会上发布卵巢癌治疗领先细胞治疗候选药物的新临床前数据
GRI Bio Inc - 试验达到主要终点及某些次要终点;GRI-0621 耐受性良好 - SEC 备案
美股速递 · 12-08 21:14
GRI Bio Inc - 试验达到主要终点及某些次要终点;GRI-0621 耐受性良好 - SEC 备案
GRI Bio Inc - 接收特发性肺纤维化2a期临床试验的初步数据 - SEC备案
美股速递 · 12-08 21:13
GRI Bio Inc - 接收特发性肺纤维化2a期临床试验的初步数据 - SEC备案
知名代理顾问公司ISS建议股东使用白色代理卡为Neuphoria的两位董事提名人投票
美股速递 · 12-08 21:07
知名代理顾问公司ISS建议股东使用白色代理卡为Neuphoria的两位董事提名人投票
Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay
美股速递 · 12-08 21:06
Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay
Mirum Pharmaceuticals:与医疗投资者联络组达成私募协议
美股速递 · 12-08 21:03
Mirum Pharmaceuticals:与医疗投资者联络组达成私募协议
Solid Biosciences将在第22届全球心血管临床试验论坛上展示其专有的下一代Aav-Slb101载体和心脏基因疗法管线
美股速递 · 12-08 21:03
Solid Biosciences将在第22届全球心血管临床试验论坛上展示其专有的下一代Aav-Slb101载体和心脏基因疗法管线
Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议,扩展在罕见疾病领域的全球领导地位
美股速递 · 12-08 21:03
Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议,扩展在罕见疾病领域的全球领导地位
加载更多
公司概况
公司名称:
生物科技
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1117.4933,"timestamp":1765227599999,"preClose":1129.6754,"halted":0,"volume":802034279,"delay":0,"changeRate":-0.010784,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-12.182129,"latestTime":"12-08 16:00:00 EST","open":1129.6779,"high":1135.3602,"low":1116.0715,"amount":20767913422.441242,"amplitude":0.017075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765242000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.241142,"peRate":-123.546101,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1180993297","title":"Praxis Precision Medicines, Inc.:单药疗法研究Power3计划于2026年上半年启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1180993297","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180993297?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:47","pubTimestamp":1765230438,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc.:单药疗法研究Power3计划于2026年上半年启动","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRAX","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1107497688","title":"因塞特医疗在2025年ASH大会上发布更新的积极数据,巩固了其首个靶向Mutcalr单克隆抗体Inca033989在原发性血小板增多症患者中的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1107497688","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107497688?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:39","pubTimestamp":1765229946,"startTime":"0","endTime":"0","summary":"因塞特医疗在2025年ASH大会上发布更新的积极数据,巩固了其首个靶向Mutcalr单克隆抗体Inca033989在原发性血小板增多症患者中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4139","INCY","BK4550","BK4585"],"gpt_icon":0},{"id":"1116613840","title":"Assembly Biosciences发布长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究积极中期结果,显示复发性生殖器单纯疱疹的病毒排泄率和经病毒确认的生殖器损伤率均有所降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1116613840","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116613840?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:14","pubTimestamp":1765228452,"startTime":"0","endTime":"0","summary":"Assembly Biosciences发布了有关其长效解旋酶-引物酶抑制剂候选药物Abi-1179和Abi-5366的1B期临床研究的积极中期结果,研究表明,复发性生殖器单纯疱疹患者的病毒排泄率和经病毒确认的生殖器损伤率均有所降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4139"],"gpt_icon":0},{"id":"1159387466","title":"Cardiff Oncology公布在ASH 2025中与Onvansertib联合进行的慢性骨髓单核细胞白血病的临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159387466","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159387466?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:06","pubTimestamp":1765227976,"startTime":"0","endTime":"0","summary":"Cardiff Oncology公布在ASH 2025中与Onvansertib联合进行的慢性骨髓单核细胞白血病的临床试验数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRDF"],"gpt_icon":0},{"id":"1183383189","title":"Arcutis加强董事会 新任命Amit Munshi并致敬退休的Bhaskar Chaudhuri","url":"https://stock-news.laohu8.com/highlight/detail?id=1183383189","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183383189?lang=zh_cn&edition=full","pubTime":"2025-12-09 05:00","pubTimestamp":1765227610,"startTime":"0","endTime":"0","summary":"Arcutis加强董事会 新任命Amit Munshi并致敬退休的Bhaskar Chaudhuri","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARQT","BK4139"],"gpt_icon":0},{"id":"1113707869","title":"Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1113707869","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113707869?lang=zh_cn&edition=full","pubTime":"2025-12-08 23:43","pubTimestamp":1765208596,"startTime":"0","endTime":"0","summary":"Kura Oncology Inc - Komzifti与Venetoclax和Azacitidine三重组合在新诊断和复发/难治性设置中耐受良好","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KURA","BK4505"],"gpt_icon":0},{"id":"2589272354","title":"Syndax公布AML联合疗法强劲数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2589272354","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589272354?lang=zh_cn&edition=full","pubTime":"2025-12-08 23:42","pubTimestamp":1765208520,"startTime":"0","endTime":"0","summary":"美股周一早盘,临床阶段的生物制药公司Syndax(SNDX)股价下跌3.2%。该公司在2025年美国血液学会(ASH)年会上展示了revumenib联合疗法的最新数据,在新诊断和移植后急性髓系白血病患者队列中显示出高缓解率和高微小残留病阴性率。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-08/doc-inhachkx2122015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4109","SNDX","ASH","BK4139","LU2463526074.USD"],"gpt_icon":0},{"id":"1152493085","title":"Recursion Pharmaceuticals股价上涨6.1%,因其实验性疗法在稀有疾病试验中减少了息肉生长","url":"https://stock-news.laohu8.com/highlight/detail?id=1152493085","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152493085?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:34","pubTimestamp":1765204493,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals股价上涨6.1%,因其实验性疗法在稀有疾病试验中减少了息肉生长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4609","BK4611","BK4139","RXRX","BK4539"],"gpt_icon":0},{"id":"1187648483","title":"ARCELLX, INC. 股份上涨10%,因公司公布其多发性骨髓瘤癌症疗法中期试验的积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187648483","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187648483?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:34","pubTimestamp":1765204460,"startTime":"0","endTime":"0","summary":"ARCELLX, INC. 股份上涨10%,因公司公布其多发性骨髓瘤癌症疗法中期试验的积极数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACLX"],"gpt_icon":0},{"id":"1148020207","title":"Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨,接近一年高点,最后上涨20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148020207","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148020207?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:34","pubTimestamp":1765204452,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨,接近一年高点,最后上涨20.5%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"1137824651","title":"Mirum Pharma首席执行官表示,Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1137824651","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137824651?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:43","pubTimestamp":1765201436,"startTime":"0","endTime":"0","summary":"Mirum Pharma首席执行官表示,Brelovitug的加入将使其罕见疾病组合的收入潜力超过40亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1101132122","title":"Coherus公布六年Jupiter-02随访结果显示Loqtorzi®联合化疗几乎使鼻咽癌的中位整体生存期增加一倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1101132122","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101132122?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:33","pubTimestamp":1765200807,"startTime":"0","endTime":"0","summary":"Coherus公布六年Jupiter-02随访结果显示,Loqtorzi®联合化疗几乎使鼻咽癌的中位整体生存期增加一倍。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRS","BK4535","BK4139"],"gpt_icon":0},{"id":"1111619319","title":"Ernexa Therapeutics在美国血液学会年会上发布卵巢癌治疗领先细胞治疗候选药物的新临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1111619319","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111619319?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:31","pubTimestamp":1765200685,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics在美国血液学会年会上发布卵巢癌治疗领先细胞治疗候选药物的新临床前数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"gpt_icon":0},{"id":"1197256579","title":"GRI Bio Inc - 试验达到主要终点及某些次要终点;GRI-0621 耐受性良好 - SEC 备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1197256579","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197256579?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:14","pubTimestamp":1765199651,"startTime":"0","endTime":"0","summary":"GRI Bio Inc - 试验达到主要终点及某些次要终点;GRI-0621 耐受性良好 - SEC 备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4139","BK4007"],"gpt_icon":0},{"id":"1109567142","title":"GRI Bio Inc - 接收特发性肺纤维化2a期临床试验的初步数据 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1109567142","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109567142?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:13","pubTimestamp":1765199624,"startTime":"0","endTime":"0","summary":"GRI Bio Inc - 接收特发性肺纤维化2a期临床试验的初步数据 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"1186846363","title":"知名代理顾问公司ISS建议股东使用白色代理卡为Neuphoria的两位董事提名人投票","url":"https://stock-news.laohu8.com/highlight/detail?id=1186846363","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186846363?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:07","pubTimestamp":1765199235,"startTime":"0","endTime":"0","summary":"知名代理顾问公司ISS建议股东使用白色代理卡为Neuphoria的两位董事提名人投票","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NEUP"],"gpt_icon":0},{"id":"1114154154","title":"Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay","url":"https://stock-news.laohu8.com/highlight/detail?id=1114154154","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114154154?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:06","pubTimestamp":1765199171,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals拟以2.5亿美元现金、3.7亿美元公司普通股以及最多2亿美元的销售里程碑付款收购Bluejay。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK4139"],"gpt_icon":0},{"id":"1168670915","title":"Mirum Pharmaceuticals:与医疗投资者联络组达成私募协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1168670915","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168670915?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765199025,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals:与医疗投资者联络组达成私募协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0},{"id":"1150848586","title":"Solid Biosciences将在第22届全球心血管临床试验论坛上展示其专有的下一代Aav-Slb101载体和心脏基因疗法管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1150848586","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150848586?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765199021,"startTime":"0","endTime":"0","summary":"Solid Biosciences将在第22届全球心血管临床试验论坛上展示其专有的下一代Aav-Slb101载体和心脏基因疗法管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","BK4139"],"gpt_icon":0},{"id":"1133302222","title":"Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议,扩展在罕见疾病领域的全球领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1133302222","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133302222?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:03","pubTimestamp":1765198995,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals达成收购Bluejay Therapeutics的最终协议,扩展在罕见疾病领域的全球领导地位","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MIRM"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}